THE LIBRARY: WEBINAR
IT challenges for the mobile health market
The mobile health market is moving rapidly, with apps now helping patients collect health data and physicians tapping into that data remotely. How can technologists make sure the apps adequately protect patient information? Join as we examine mobile health advances, patient privacy challenges, and how the FDA is evolving its thinking on regulating mobile apps. Register Today!
Latest Commentary
EVENTS
- Supplying Safe Medicines to Patients June 12 — Exton, PA
- Oak Ridge National Lab Biosurveillance Symposium 2013June 17, 2013 — Alexandria, VA
- BioImmersion Three-Day CourseJuly 10-12 — Chicago, IL
Press Releases
- 22 May 2013 - Changes to GSK Manufacturing Site in Melbourne
- Vortioxetine, a new multimodal agent in development for the treatment of major depression, shows effects on cognitive function in several preclinical animal models
- EOS imaging Announces Sales Force Structure in Asia
- Study finds COPD is over-diagnosed among uninsured patients
- Clavis Pharma ASA : Appointments of Interim Chairman and Acting CEO
- More Press Releases
Featured Jobs
-
Sr. Manufacturing Process Lead Job
Celgene Corporation - Basking Ridge NJ US -
Quality Control Lead
Infinity Pharmaceuticals - Cambridge MA -
Principal Scientist - Biochemistry
Syros Pharmaceuticals - -
Sr. Manufacturing Process Lead Job
Celgene Corporation - Basking Ridge NJ US -
Project Manager, R&D
Regado Biosciences, Inc. -
Regeneron's chief scientist spotlights potential blockbuster allergy drug
With one likely blockbuster on the market in Eylea and at least three others in development, Regeneron Chief Scientific Officer Dr. George Yancopoulos has plenty to keep him busy for the next several years. Read the full feature >>
Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups
Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in the Boston area and The Netherlands, he told FierceBiotech in an interview. Read more >>
Which Big Biotechs are hitting the gas pedal on R&D spending?
The R&D numbers for the top 10 biotechs may only amount to a fraction of what you'll find in Big Pharma. But unlike the giants, which are trying to keep a lid on multibillion-dollar budgets, you'll find a much faster crowd when you turn your gaze to the biotechs.
MedImmune chief taps top prospects, hunts new biologics deals
Last year AstraZeneca's MedImmune did about 20 biologics deals, not counting the academic pacts it assembled. Bahija Jallal, head of R&D, tells FierceBiotech there will be no letup in talent scouting: "If we do as little or more than last year, I would be happy."
Guidelines for contributing an Industry Voices column to Fierce
Industry Voices is a platform for life sciences professionals to provide their particular view of a current technology, industry, or business topic. Here are our guidelines and submission process.
Hope to see you in Chicago for #BIO2013
FierceBiotech hits the road
I've got a busy schedule of events coming up over the next few months. First, if you're headed to Chicago for BIO later this month, I hope you'll come by my executive breakfast. The big challenge in drug development now is figuring out how to do much faster, more efficient clinical drug programs. -- John Carroll, Editor-in-Chief. Follow me on Twitter.
FierceBiotech believes in storytelling: Check it out
Our readers hunger for context and analysis of major developments in the industry. We work hard to deliver such insights in all of our daily reports. Yet we aim to go deeper into stories with additional feature articles and special reports.
Clashing stands of India, U.K. on drug patents, R&D will offer clear lessons
Today two countries on opposite sides of the world took radically different stances on pharma patents that will have a big impact on the future of drug R&D.
Join the R&D revolution now
I'll be sitting down with four top R&D executives from some of the biggest pharma operations around the globe next month to see where we go from here. I hope to see you there. And if you sign up today, you can still get the early-bird special. The price goes up tomorrow. You can register here.